Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Medicina (Kaunas) ; 58(12)2022 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-36557046

RESUMO

Hypertrophic obstructive cardiomyopathy (HOCM) is one of the most common hereditary heart diseases. The severely hypertrophied interventricular septum combined with the systolic anterior movement (SAM) of the mitral valve (MV) frequently cause a significant pressure gradient in the left ventricular outflow tract associated with varying degrees of mitral regurgitation (MR). We present the case of a 64-year-old female patient who was diagnosed with HOCM two years ago and was admitted to the Institute of Cardiovascular Disease with exertion dyspnea and fatigue. Transthoracic echocardiography revealed concentric, asymmetrical left ventricular hypertrophy, an elongated anterior mitral leaflet (AML) and a significant SAM causing severe regurgitation, with indication for valvular replacement Monoamine oxidase (MAO), a mitochondrial enzyme, with 2 isoforms, MAO-A and B, has emerged as an important source of reactive oxygen species (ROS) in the cardiovascular system, but literature data on its expression in valvular tissue is scarce. Therefore, we assessed MAO-A and B gene (qPCR) and protein (immune fluorescence) expression as well as ROS production (spectrophotometry and confocal microscopy) and in the explanted MV harvested during replacement surgery. MAO expression and ROS production (assessed by both methods) were further augmented following ex vivo incubation with angiotensin II, an effect that was reversed in the presence of either MAO-A (clorgyline) or B (selegiline) inhibitor, respectively. In conclusion, MAO isoforms are expressed at the level of severely impaired mitral valve in the setting of HOCM and can be induced in conditions that mimic the activation of renin-angiotensin-aldosterone system. The observation that the enzyme can be modulated by MAO inhibitors warrants further investigation in a patient cohort.


Assuntos
Cardiomiopatia Hipertrófica , Insuficiência da Valva Mitral , Feminino , Humanos , Pessoa de Meia-Idade , Valva Mitral/cirurgia , Monoaminoxidase , Espécies Reativas de Oxigênio , Insuficiência da Valva Mitral/complicações
2.
Biomolecules ; 11(6)2021 05 30.
Artigo em Inglês | MEDLINE | ID: mdl-34070757

RESUMO

Cardiovascular disorders are leading mortality causes worldwide, often with a latent evolution. Vascular health depends on endothelial function, arterial stiffness, and the presence of atherosclerotic plaques. Preventive medicine deserves special attention, focusing on modifiable cardiovascular risk factors, including diet. A diet rich in fruits and vegetables has well-known health benefits, especially due to its polyphenolic components. Anthocyanins, water-soluble flavonoid species, responsible for the red-blue color in plants and commonly found in berries, exert favorable effects on the endothelial function, oxidative stress, inhibit COX-1, and COX-2 enzymes, exert antiatherogenic, antihypertensive, antiglycation, antithrombotic, and anti-inflammatory activity, ameliorate dyslipidemia and arterial stiffness. The present review aims to give a current overview of the mechanisms involved in the vascular protective effect of anthocyanins from the human diet, considering epidemiological data, in vitro and in vivo preclinical research, clinical observational, retrospective, intervention and randomized studies, dietary and biomarker studies, and discussing preventive benefits of anthocyanins and future research directions.


Assuntos
Antocianinas/uso terapêutico , Aterosclerose/tratamento farmacológico , Dislipidemias/tratamento farmacológico , Endotélio Vascular/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Placa Aterosclerótica/tratamento farmacológico , Rigidez Vascular/efeitos dos fármacos , Antocianinas/química , Antocianinas/metabolismo , Aterosclerose/metabolismo , Aterosclerose/mortalidade , Dislipidemias/metabolismo , Dislipidemias/mortalidade , Humanos , Placa Aterosclerótica/metabolismo , Placa Aterosclerótica/mortalidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA